Top Page
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh
(Sydney:EBR)
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh (EBR) vs. iShares MSCI Australia ETF (EWA)
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Business Overview & Revenue Model
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | ― | -24.66M | -23.62M | ― | ― |
| Net Income | ― | -35.04M | -33.09M | ― | ― |
Balance Sheet | |||||
| Total Assets | 73.56M | 78.90M | 71.68M | 85.42M | 8.40M |
| Cash, Cash Equivalents and Short-Term Investments | 60.66M | 72.32M | 63.53M | 78.24M | 5.88M |
| Total Debt | 41.40M | 41.59M | 21.59M | 4.81M | 33.23M |
| Total Liabilities | 49.20M | 47.84M | 27.73M | 9.53M | 46.05M |
| Stockholders Equity | 24.36M | 31.06M | 43.95M | 75.90M | -37.65M |
Cash Flow | |||||
| Free Cash Flow | -41.50M | -33.05M | -31.09M | ― | ― |
| Operating Cash Flow | -41.23M | -32.70M | -30.36M | ― | ― |
| Investing Cash Flow | 1.11M | -8.64M | -49.35M | -906.81K | ― |
| Financing Cash Flow | 32.48M | 40.47M | 17.01M | 95.76M | 16.41K |
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Technical Analysis
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
80 Outperform | AU$57.82B | 29.08 | 25.23% | 0.99% | 10.54% | 38.69% | |
70 Outperform | $20.29B | 54.82 | 20.61% | 1.39% | 6.35% | 5.97% | |
70 Neutral | $124.63B | 29.91 | 15.38% | 1.65% | 8.00% | 9.09% | |
68 Neutral | $1.16B | 70.15 | 9.23% | ― | 10.79% | 5.20% | |
61 Neutral | $8.92B | 1,091.01 | 0.52% | 2.06% | 7.25% | -99.04% | |
52 Neutral | $7.35B | -0.07 | -63.71% | 2.81% | 16.17% | 0.03% | |
35 Underperform | AU$451.57M | ― | -225.07% | ― | ― | ― |
EBR Systems, Inc. Shs Chess Depository Interests Repr 1 Sh Corporate Events
EBR Systems, Inc. has submitted an application to the U.S. Centers for Medicare & Medicaid Services for the Transitional Pass-Through reimbursement scheme for their WiSE CRT System. This move follows recent FDA approval and aims to facilitate hospital adoption of the system by providing a clear reimbursement pathway for outpatients. If approved, the scheme will be effective from October 2025, enhancing Medicare payments for hospitals and supporting the commercial rollout of the WiSE CRT System in the U.S. The CMS has already recommended the system for New Technology Add-On Payment for inpatients, indicating strong support for EBR’s innovative technology.
EBR Systems, Inc. has appointed Mr. Kobe Li as an additional person responsible for communications with the ASX, enhancing its compliance and governance capabilities. This strategic appointment is expected to strengthen the company’s operational efficiency and industry positioning, potentially benefiting stakeholders by ensuring more robust communication and adherence to regulatory requirements.
EBR Systems, Inc. has issued a Corporate Governance Statement outlining its compliance with the ASX Corporate Governance Council’s 4th edition Principles and Recommendations. The company largely adheres to these guidelines, with deviations attributed to its current size and operational scale. The statement highlights the company’s commitment to transparency and accountability, detailing its board charter, appointment processes for directors and executives, and the provision of essential information to security holders.
EBR Systems, Inc. has released its Annual Report for 2024, highlighting its commitment to transforming the lives of patients with heart failure through the development of technology that enables physicians to deliver optimal cardiac pacing. The report includes operational highlights, an executive letter, and an overview of their WiSE® Technology, which is central to their innovative approach in the healthcare industry.
EBR Systems, Inc. has announced the details of its 2025 Annual Meeting, which will be held virtually to accommodate its global stakeholders. The company has also released its Annual Report and Corporate Governance Statement for the year ending December 2024, reflecting its ongoing commitment to transparency and shareholder engagement. This announcement underscores EBR’s strategic focus on leveraging its innovative WiSE technology to enhance its market position and address the needs of patients with cardiac rhythm diseases.
EBR Systems, Inc. has announced a webinar to discuss the FDA PMA approval, featuring key executives including the President & CEO, Chief Regulatory Officer, and Chief Commercial Officer. This announcement is significant for the company as it highlights a major regulatory milestone, potentially impacting its market position and operations positively.
EBR Systems, Inc. announced the issuance of 328,800 unquoted equity securities in the form of options expiring on various dates at various prices. These securities are part of an employee incentive scheme and are not intended to be quoted on the ASX, reflecting the company’s strategy to incentivize its workforce and potentially align employee interests with company performance.
EBR Systems, Inc. has announced the cessation of 243,001 securities due to the lapse of conditional rights that were not satisfied. This announcement may impact the company’s capital structure and could have implications for stakeholders, as it reflects adjustments in the company’s securities management.
EBR Systems, Inc. has announced the filing of its preliminary proxy statement for its upcoming virtual Annual Meeting of Stockholders, scheduled for May 2025. The agenda includes the re-election of directors, ratification of past securities issuance, and amendments to the company’s equity incentive plan and certificate of incorporation. This meeting is significant for stakeholders as it will address key governance and operational matters, potentially impacting the company’s strategic direction and compliance with regulatory requirements.
EBR Systems, Inc. has announced a new issuance of 45,000 securities to be quoted on the Australian Securities Exchange (ASX). This move is part of an employee incentive scheme, indicating the company’s efforts to motivate and retain talent, which could enhance its operational capabilities and market position.
EBR Systems, Inc. has released its Quarterly Cash Flow Report for the quarter ending December 31, 2024, highlighting a strategic shift in its financial operations. The company has reduced research and development costs by capitalizing on pre-launch inventory, while administrative costs have risen due to preparations for a U.S. Securities and Exchange Commission registration. This financial maneuvering reflects EBR’s ongoing efforts to strengthen its market position and operational efficiency, with potential implications for stakeholders as the company advances its innovative cardiac pacing solutions.
EBR Systems, Inc. announced the submission of the final module of its Premarket Approval application for the WiSE CRT System to the FDA, with regulatory approval expected by April 2025 and a commercial launch anticipated in the second half of 2025. The company has also been accepted into the CMS’s TCET reimbursement pathway, signed a lease for a new manufacturing facility, and completed a significant capital raise, positioning it well for future growth and market entry.
EBR Systems, Inc. reported a net loss of $40.8 million for the year ending December 31, 2024, marking a 16.4% increase from the previous year. The loss was attributed to higher general and administrative expenses and increased interest expenses due to additional borrowings. The company did not declare any dividends and reported a decrease in net tangible assets per share. Cash and marketable securities also declined to $66 million from $73.4 million the previous year.
EBR Systems, Inc. announced the issuance of 300,000 unquoted equity securities, specifically options expiring on various dates at various prices, as part of an employee incentive scheme. This move reflects the company’s strategy to motivate and retain its workforce, potentially impacting its operational efficiency and market competitiveness.
EBR Systems, Inc. has announced a new application for the quotation of securities on the Australian Securities Exchange (ASX). The company is set to quote 4,294 securities under the code EBR CDI 1:1 US PERSON PROHIBITED, with an issue date of February 28, 2025. This move is part of an employee incentive scheme, and the securities are not subject to transfer restrictions. This announcement may enhance the company’s market presence and provide additional liquidity options for stakeholders.
EBR Systems, Inc. has announced a rescheduling of its Annual Meeting of Stockholders, now set for May 22, 2025, as a virtual event. This change reflects the company’s commitment to accommodating stakeholders across different time zones. The meeting will provide a platform for stakeholders to engage with the company’s strategic direction and operations, with further details to be released closer to the date.
EBR Systems, Inc. announced its intention to release its annual report on Form 10-K for the year ending December 31, 2024, on March 25, 2025. This aligns with the company’s strategy to file financial reports simultaneously with the SEC and ASX, following SEC regulations. The announcement reflects EBR’s commitment to transparency and regulatory compliance, potentially impacting its market positioning and stakeholder confidence.
EBR Systems, Inc. has announced the issuance of 200,000 unquoted equity securities as part of an employee incentive scheme, which are not intended to be quoted on the ASX. This move reflects the company’s strategy to incentivize its workforce and potentially strengthen its position in the healthcare technology market, aligning employee interests with company growth.
EBR Systems, Inc. announced that its Annual Meeting of Stockholders will be held virtually on 29 May 2025. The meeting will provide shareholders with real-time participation through online voting and question submissions. The company’s innovative wireless cardiac pacing technology positions it uniquely in the market by potentially offering a more reliable and effective solution for heart failure patients, which could have significant implications for stakeholders in the cardiac rhythm management industry.
EBR Systems, Inc. announced the cessation of 208,276 securities due to the lapse of conditional rights as the specified conditions were not met or became incapable of being satisfied. This development may impact the company’s financial structure and could have implications for investors regarding the future availability of securities.
EBR Systems, Inc. has announced the application for quotation of 1,770,830 securities on the Australian Securities Exchange (ASX). This issuance is part of an employee incentive scheme, indicating the company’s strategic focus on rewarding and retaining its workforce. The announcement reflects EBR Systems’ commitment to leveraging financial markets for growth and may impact its market dynamics by increasing investor interest and potentially enhancing liquidity.